CW January 2003
Volume 12Issue Number 1 January 2003 ISSN 10593802 Chemotherapy Combinations Active, Safe for Esophago-gastric CancerThe first results of a large, randomized, phase III multicenter trial show promising activity and toxicity profiles among advanced esophago-gastric cancer patients treated with capecitabine (Xeloda, Roche) or oxaliplatin (Eloxatin, Sanofi) combinations with 5-FU or cisplatin (Platinol, Bristol-Myers Squibb).
Go to Previous Page Go to Next Page Source & Addtional Reading N. Tebbutt, 20th Annual Chemotherapy Foundation Symposium in New York. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW January 2003Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
